There is an urgent unmet need for biomarker solutions that provide robust clinical trial endpoints for evaluating severity and progression in neuromuscular…
Insights Articles
Revealing the true impact of drug therapies for metabolic diseases through weight-invariant fat distribution assessment using AMRA’s Z-Scores
As the rise of incretin-based therapies has changed the face of type 2 diabetes (T2D) and obesity care, the treatment development landscape…
AMRA’s MRI assessments provide a unique understanding of weight loss in obesity
Recent studies have demonstrated that the magnitude of weight-reduction associated with the advent of next-generation obesity and type II diabetes (T2D) pharmacological…